Crohns disease pathobiont adherent-invasive E coli disrupts epithelial mitochondrial networks with implications for gut permeability
It belongs to a novel class of agents known as triple receptor agonists , meaning it simultaneously activates three distinct hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor
CrossRef Augmenting conventional criteria: a CT-based deep learning radiomics nomogram for early recurrence risk stratification in hepatocellular carcinoma after liver transplantation Ziqian Wu, Danyang Liu, Siyu Ouyang, Jingyi Hu, Jie Ding, Qiu Guo, Jidong Gao, Jiawen Luo, Ke Ren Insights into Imaging .2025;[Epub] CrossRef Exploration of the Mechanism of Action of Dendrobium officinale in the Treatment of Liver Cancer Based on Network Pharmacology, Molecular Docking and in vitro Validation Shuimeng Zhan, Xinyan Lu, Hongyan Guo, Yang Liu, Zhi Li, Wei Xu, Fang Xia, Huanjun Tang, Yi Tian, Jing Chen, Xuan Lin Journal of Hepatocellular Carcinoma .2025
Bodybuilding Health+ Review 2026: GLP-1, Sermorelin, NAD+ and Tadalafil Pricing, Provider Structure, and the FDA Deadline Every Compounded GLP-1 Patient Needs to Know Compounded Semaglutide and Tirzepatide Starting at $179/mo, Sermorelin ODT and Injection Options, NAD+ Nasal Spray and Injection Bundles, Provider-Guided Tadalafil for Vascular Health and BPH - All 50 States, Cash-Pay, No Insurance Required, Prescription Approval Not Guaranteed, and What the FDA's June 29, 2026 Comment Deadline Means for Anyone Starting a Compounded GLP-1 Program This Month BOCA RATON, Fla., May 7, 2026 (Newswire.com) - Disclosure: This article is a sponsored advertorial produced for informational purposes only
